Based on the Egetis Therapeutics AB stock forecast from 0 analysts, the average analyst target price for Egetis Therapeutics AB is not available over the next 12 months. Egetis Therapeutics AB’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Egetis Therapeutics AB is Neutral, which is based on 0 positive signals and 0 negative signals. At the last closing, Egetis Therapeutics AB’s stock price was SEK 4.30. Egetis Therapeutics AB’s stock price has changed by +7.42% over the past week, +2.19% over the past month and 0% over the last year.
No recent analyst target price found for Egetis Therapeutics AB
No recent average analyst rating found for Egetis Therapeutics AB
Company Overview Egetis Therapeutics AB
Egetis Therapeutics AB (publ), a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of MCT8 deficiency, a rare inborn error of thyroid hormone signaling that is in phase IIb/III clinical trial. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is based in Stockholm, Sweden. Address: Read Less
Egetis Therapeutics AB (publ), a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce t...Read More
N/A
N/A
23
N/A
SEK
UK
Adjusted Closing Price for Egetis Therapeutics AB (0ABW:LSE)
Loading...
Unadjusted Closing Price for Egetis Therapeutics AB (0ABW:LSE)
Loading...
Share Trading Volume for Egetis Therapeutics AB Shares
Loading...
Compare Performance of Egetis Therapeutics AB Shares
Symbol
Capital Gain
Dividend Return
Total Return
Loading...
Loading...
Technical Indicators for 0ABW:LSE
Assets
Top Holdings
N/A
Top Sectors
Top Regions
Stocks Similar To Egetis Therapeutics AB (Sector: )
Frequently Asked Questions About Egetis Therapeutics AB (0ABW:LSE) Stock
Stock Target Advisor's fundamental analysis for Egetis Therapeutics AB's stock is Neutral.
Unfortunately we do not have enough data on 0ABW:LSE's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 0ABW:LSE's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on 0ABW:LSE's stock to indicate if its overvalued.
The last closing price of 0ABW:LSE's stock was SEK 4.30.
Unfortunately we do not currently have any market capitalization data for 0ABW:LSE's stock.
Unfortunately we do not have enough analyst data on 0ABW:LSE's stock to indicate whether its price will go up or not.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
There is nothing we particularly dislike
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 0ABW:LSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
